Home / Health / EMA Approves Expanded NaMuscla Use for Myotonia Treatment
EMA Approves Expanded NaMuscla Use for Myotonia Treatment
1 Jul
Summary
- EMA approved new dosage strengths for NaMuscla, including 62 mg and 83 mg capsules.
- NaMuscla's indications are revised to include symptomatic treatment of myotonia.
- The drug is now approved for children, adolescents, and adults with myotonic disorder.
The European Medicines Agency (EMA) has authorized changes to the marketing authorization for NaMuscla, a treatment for myotonic disorder. This significant update supports the drug's expanded use across various age groups and introduces new dosage options.
The approval introduces two new capsule strengths: 62 mg and 83 mg, which will be available alongside the existing 167 mg formulation. These changes are part of a revised indication for NaMuscla, focusing on the symptomatic treatment of myotonia.
NaMuscla is now indicated for children aged 6 to 11 years who weigh at least 20 kg, as well as for adolescents and adults. This expanded access aims to provide improved symptomatic relief for individuals diagnosed with non-dystrophic myotonic disorder.
